News and Announcements
Actinogen Medical Investor Research Update
- Published October 13, 2016 11:22AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
September 27, 2016
Actinogen Medical (ASX:ACW) met again with Baker Young Stockbrokers to discuss Xanamem™’s past resear
Best Risk vs Reward Play in Alzheimer’s Dementia
Baker Young maintains coverage of Actinogen Medical with a BUY recommendation and value ACW $0.39 per share base case and $1.12 per share optimistic case using the probability weighted DCF methodology.
Alastair Murray
Analyst, Baker Young Corporate
“We see XanADu, the Phase II trial of Xanamem™ for the treatment of mild Alzheimer’s disease positioning Actinogen amongst significantly larger peers (see Table inside report). Going forward Actinogen has a strong cash position to progress through the pivotal Phase II clinical trial, which the company hopes will show Xanamem™ to be an effective and safe treatment for mild Alzheimer’s disease. We believe positive results from this Phase II trial will likely result in a significant partnering transaction (potential for a total deal size of up to $1B upfront & milestones + royalties) given the current unmet market need, comparable similar transactions and Big Pharma’s desire to bring new effective treatments for dementia to market. We believe ACW at current levels represents compelling value on a risk-reward basis”
To view the Baker Young Report, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
